Close

What are ADC's

Our services

ADC Review
is made possible by:




NCT01409135 (Clinical Trial/ ASG-22ME/ AGS-22M6E)

Study Title
A Study of the Safety and Pharmacokinetics of AGS-22M6E in Subjects with Malignant Solid Tumors that Express Nectin-4 (NCT01409135)

Trial Description
A study examining the safety of AGS-22M6E (now known as AGS-22ME) or ASG-22CE administered as monotherapy therapy in subjects with malignant solid tumors that express Nectin-4. This trial is sponsored by Seattle Genetics/Astellas Pharma Inc. [1]

Study Data

  • Condition: Solid Tumors That Express Nectin-4
  • Interventions:
    • Drugs used in this trial
    • AGS-22M6E (AGS-22ME)
    • ASG-22CE
  • Phase: I
  • Estimated Enrollment: 34
  • Start: June 2011
  • Estimated Completion: June 2015
  • Last verified: October 2015

Study Schematic

1935

Click here to Return to Drug map


Last Editorial review: July 12, 2106
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.

Copyright © 2015-2016 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.


Share

Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...


Skip to toolbar